Quantcast
Last updated on April 24, 2014 at 10:16 EDT

Latest Steven Rosenberg Stories

2014-03-05 10:57:36

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments. Patients who showed responses to the drug, nivolumab (anti-PD-1;...

2012-05-21 02:25:48

LOS ANGELES, May 21, 2012 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, announces the posting of the following Letter to Shareholders to the Investors section of the Company's website at www.genesis-biopharma.com. In addition, on May 15, 2012, the Company filed with the U.S. Securities and Exchange Commission its Quarterly Report for the three months ended March 31, 2012 on Form 10-Q. The Form 10-Q includes...

2012-03-06 06:21:30

(Ivanhoe Newswire)-- Those suffering from Melanoma may have new hope. A recent study shows that a patient's own cells may reduce advanced melanoma and send the cancer into remission. Cassian Yee, M.D., a member of the Clinical Research Division of Fred Hutchinson Cancer Research Center, had a goal to find the ideal cellular environment in which to infuse 15 billion to 20 billion cancer-fighting CD8+ T cells so that they remain for as long as possible in the body to battle the tumors. The...

2012-02-07 21:09:36

New therapy combination prolongs survival in dogs and furthers research for human trials A new immunotherapy for companion dogs with advanced-stage non-Hodgkin lymphoma (NHL) has been shown to improve survival while maintaining quality of life, according to a study published in the journal Scientific Reports. The study resulted from a collaboration between The University of Texas MD Anderson Children´s Cancer Hospital in Houston and Texas A&M University College of Veterinary...

2011-11-17 07:00:00

LOS ANGELES, Nov. 17, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTCBB: GNBP), a biotechnology company developing targeted cancer immunotherapies, today announced that Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch at the National Cancer Institute, has joined the Company's Scientific and Medical Advisory Board. Dr. Rosenberg also is Professor of Surgery at the Uniformed Services University of Health Sciences and at the George Washington University School of Medicine and...

2011-08-30 07:00:00

LOS ANGELES, Aug. 30, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC.BB: GNBP), a biotechnology company developing targeted cancer therapies, today announced that the following Letter to Shareholders will be posted today to the investor relations section of the Company's website at www.genesis-biopharma.com. In addition, on August 22, 2011, the Company filed with the U.S. Securities and Exchange Commission its Quarterly Report for the three and six months ended June 30, 2011 on Form...

2011-08-10 06:00:00

LOS ANGELES, Aug. 10, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, today announced it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Under the terms of the five-year cooperative research and development agreement, Genesis Biopharma will work with Steven A. Rosenberg, M.D., Ph.D., the NCI Surgery Branch Chief, to develop adoptive cell...

2011-02-01 12:29:33

Researchers have found that a novel form of personalized therapy that genetically engineers a patient's own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma, representing a potentially new therapeutic approach against these and other cancers. The technique, called adoptive immunotherapy, works with the body's immune system to fight cancer. Immune cells, called T lymphocytes, are removed, modified, expanded in large numbers, and given...

2010-11-25 08:16:41

(Ivanhoe Newswire) -- Complete remission of cancer is what many of the more than 68,000 patients who will be diagnosed with melanoma this year would love to hear.A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer. Indiana University School of Medicine researchers used a modified lentivirus to introduce a potent anti-melanoma T cell receptor gene into the hematopoietic stem...

2010-11-18 16:54:44

A potent anti-tumor gene introduced into mice with metastatic melanoma has resulted in permanent immune reconfiguration and produced a complete remission of their cancer, according to an article to be published in the December 2010 issue of the Journal of Clinical Investigation. The online version is now available. Indiana University School of Medicine researchers used a modified lentivirus to introduce a potent anti-melanoma T cell receptor gene into the hematopoietic stem cells of mice....